Q-omics provides the consensus-scored TSEN15P1 profile across patient tissues and cancer cell-line models. TSEN15P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TSEN15P1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TSEN15P1 RNA expression shows 11,948 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, HNSC, and ACC as cancer lineages where TSEN15P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSEN15P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSEN15P1 survival associations across molecular data types. TSEN15P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSEN15P1 RNA expression–survival associations across cancer types. High TSEN15P1 expression shows unfavorable associations in ACC, TGCT, CESC, MESO and LIHC, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify UCS as the clearest survival context for TSEN15P1 RNA expression.
This table summarizes TSEN15P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TSEN15P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSEN15P1 shows lower tumor expression in KIRC and KICH and higher tumor expression in HNSC, LUSC, BRCA and UCEC. The HNSC box plot shows higher TSEN15P1 RNA expression in tumor versus normal tissue (log2 FC = +0.262, t-test p < 0.001).
This table shows molecular features associated with TSEN15P1 in patient tissues and cancer cell lines. In patient samples, TSEN15P1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
